Synthesis and receptor binding properties of chimeric peptides containing a μ-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 18, 2006, Pages 4839-4841

  Kawano, Susumu ^a   Ambo, Akihiro ^a   Sasaki, Yusuke ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Opioid ligand; Ac RYYRIK NH2; Chimera peptide; Receptor affinity profile

Indexed keywords

DERMORPHIN DERIVATIVE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NOCICEPTIN; NOCICEPTIN RECEPTOR AGONIST; PEPTIDE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; PHARMACOPHORE; RAT;

AMIDES; AMINO ACID SEQUENCE; INHIBITORY CONCENTRATION 50; LIGANDS; PEPTIDES; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU;

EID: 33746795407     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.06.060     Document Type: Article

References (23)

1. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour L.L., Guilemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., and Costentin J. Nature 377 (1995) 532
2. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Science 270 (1995) 792
3. Calo' G., Guerrini R., Rizzi A., Salvadori S., and Regoli D. Br. J. Pharmacol. 229 (2000) 1261
4. Munier J.-C. Eur. J. Pharmacol. 340 (1997) 1
5. Henderson G., and Macknight A.T. Trends Pharmacol. Sci. 18 (1997) 293
6. Rossi G., Leventhal L., Bolan E.A., and Pasternak G.W. J. Pharmacol. Exp. Ther. 282 (1997) 858
7. Tian J.H., Xu W., Fang Y., Mogil J.S., Grisel J.E., Grandy D.K., and Han J.S. Br. J. Pharmacol. 120 (1997) 676
8. King M., Chang A., and Pasternak G.W. Biochem. Pharmacol. 55 (1998) 1537
9. Kolesnikov Y.A., and Pasternak G.W. Life Sci. 64 (1999) 2021
10. Dooley C.T., Spaeth C.G., Berzetei-Gurske I.P., Craymer K., Adapa I.D., Brandt S.R., Houghton R.A., and Toll L. J. Pharmacol. Exp. Ther. 283 (1997) 735
11. Berger H., Albrecht E., Wallukat G., and Bienert M. Br. J. Pharmacol. 126 (1999) 555
12. Pan Y.-X., Bolan E., and Pasternak G.W. Biochem. Biophys. Res. Commun. 297 (2002) 659
13. Broccardo M., Erspamer V., Erspamer G.F., Improta G., Linari G., Melchiorri P., and Montecucchi P.C. Br. J. Pharmacol. 73 (1981) 625
14. Sasaki Y., Ambo A., and Suzuki K. Chem. Pharm. Bull. 39 (1991) 2313
15. Kohara H., Ambo A., and Sasaki Y. In: Yamada T. (Ed). Peptide Sciences 2002 (2003), Japanese Peptide Society 217-218
16. Portoghese P.S. J. Med. Chem. 44 (2001) 2259
17. Sasaki Y., and Chiba T. J. Med. Chem. 38 (1995) 3995
18. Thieriet N., Aisina J., Giralt E., Guibe F., and Albericio F. Tetrahedron Lett. 38 (1997) 7275
19. 3CN. A linear gradient elution from 10% to 50% B over 40 min was used at a flow rate of 1 ml/min, with monitoring of the eluate at 220 nm. All synthetic peptides had a purity of more than 96% on the HPLC. Amino acid analysis was carried out after 6 N HCl hydrolysis of peptides at 110 °C for 24 h. βAla was eluted at the same position as Phe.
20. Shimohigashi Y., Costa T., Chen H.C., and Rodvard D. Nature 297 (1982) 333
21. Shimohigashi Y., Ogasawara T., Koshizaka T., Waki M., Kato T., Izumiya N., Kurono M., and Yagi K. Biochem. Biophys. Res. Commun. 146 (1987) 1109
22. Costa T., Shimohigashi Y., Krumins S.A., Monson P.J., and Rodbard D. Life Sci. 31 (1982) 1625
23. Portoghese P.S., Larson D.L., Sayre L.M., Yim C.B., Ronsisvalle G., Tam S.W., and Takemori A.E. J. Med. Chem. 29 (1986) 1855